

- **Name:** Jan Trøst Jørgensen
 - **Current Position & Affiliation:** Director, Dx-Rx Institute, Fredensborg
 - **Country:** Denmark
-

• **Educational Background:**

- MS Pharm, The Faculty of Pharmaceutical Sciences, University of Copenhagen, 1983
- PhD, The Faculty of Pharmaceutical Sciences, University of Copenhagen, 1992

• **Professional Experience:**

- Jan Trøst Jørgensen brings over 40 years of R&D experience from his work in pharmaceutical and diagnostic companies, as well as academia. For more than two decades, he has concentrated primarily on companion diagnostics and drug-diagnostic co-development in oncology and has authored numerous scientific publications on these topics. He serves on editorial boards and as a reviewer for scientific journals and has acted as a referee for research foundations. In recent years, his focus has shifted towards academic research and contributing as an editor and co-author to books and special editions of scientific journals on topics related to companion diagnostics.

• **Professional Organizations:**

- American Society of Clinical Oncology (Member)
- Danish Society of Cyto and Histochemistry (Board Member)
- Danish Society of Personalized Medicine (Member)
- Danish Society of Clinical Pharmacy (Member)

• **Main Scientific Publications:**

- Jørgensen JT, Nielsen KV, Ejlersen B. Pharmacodiagnosics and Targeted Therapies: A rational approach for individualizing medical anti-cancer therapy in breast cancer. *Oncologist* 2007; 12: 397-405.
- Nielsen KV, Jørgensen JT, Schønau A, Øster A. Human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol.* 2007; 25: 4020.
- Jørgensen JT. Targeted HER2 Treatment in Advanced Gastric Cancer. *Oncology* 2010; 78: 26-33.
- Jørgensen JT. A Changing Drug Development Process in the Era of Personalized Medicine. *Drug Discov Today* 2011; 16: 891-897.
- Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. *J Cancer* 2012; 3: 137-144.
- Olsen D, Jørgensen JT. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. *Front Oncol* 2014; 4: 105.
- Jørgensen JT. Clinical application of companion diagnostics. *Trends Mol Med* 2015; 21: 405-407.
- Jørgensen JT. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. *Trends Cancer* 2016; 2: 706-712.
- Hersom M, Jørgensen JT. Companion and Complementary Diagnostics: Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer. *Ther Drug Monit.* 2018; 40: 9-16.
- Jørgensen JT. When biomarkers define a drug indication. *Expert Rev Mol Diagn.* 2018; 18: 315-317.
- Jørgensen JT, Hersom M. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology. *Clin Pharmacol Ther.* 2018; 103: 999-1008.
- Jørgensen JT. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized

Pharmacotherapy. *Oncologist*. 2019; 24: e432-e440.

- Jørgensen JT, Møllerup J, Yang H, Go N, Nielsen KB. *MET* deletion is a frequent event in gastric/gastroesophageal junction/esophageal cancer: a cross-sectional analysis of gene status and signal distribution in 1580 patients. *Ann Transl Med*. 2021; 9: 225.
- Jørgensen JT. The current landscape of the FDA approved companion diagnostics. *Transl Oncol*. 2021; 14: 101063.
- Jørgensen JT, Winther H, Askaa J, Andresen L, Olsen D, Møllerup J. A Companion Diagnostic with Significant Clinical Impact in Treatment of Breast and Gastric Cancer. *Front. Oncol*. 2021; 11: 676939.
- Jørgensen JT, Møllerup J. Companion Diagnostics and Predictive Biomarkers for *MET*-Targeted Therapy in NSCLC. *Cancers*. 2022; 14: 2150.
- Jørgensen JT. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs. *JCO Precis Oncol*. 2022; 6: e2200100.
- Jørgensen JT. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug. *Oncology*. 2023; 101: 836-842.
- Jørgensen JT. Twenty-five years with companion diagnostics. *Chin Clin Oncol*. 2023; 6: cco-23-96.
- Jørgensen JT. The impact of companion diagnostic testing on medical decision making and IVD regulations. *Expert Rev Mol Diagn*. 2024; 24: 245-247.
- Jørgensen JT. Twenty-five years with *HER2* targeted therapy. *Ann Transl Med* 2024; 12: 53.
- Jørgensen JT, Egebjerg K, Lænkholm AV, Mau-Sørensen M. Human Epidermal Growth Factor Receptor 2 Pan Tumor Indication for Trastuzumab Deruxtecan. *J Clin Oncol*. 2024; 42: 4130-4133.

• Books and Special Issue Editor:

- Molecular Diagnostics – The Key Driver of Personalized Cancer Medicine. Jørgensen JT and Winther H eds., *Pan Stanford Publishing, Singapore, 2010*.
- Drug-Diagnostic Co-Development in Oncology. Jørgensen JT ed. *Frontiers in Oncology*, November 2014. *Front Oncol*. 2014; 4: 208.
- Special Focus: In Vitro Companion Diagnostics Companion diagnostics: the key to personalized medicine. Jørgensen JT ed. *Expert Review of Molecular Diagnostics*, January 2015. *Expert Rev Mol Diagn*. 2015;15(2):153-6.
- Companion and Complementary Diagnostics: From Biomarker Discovery to Clinical Implementation. Jørgensen JT ed. *Academic Press/Elsevier, London, 2019*.
- Special Focus: Companion and complementary diagnostics: an important treatment decision tool in precision medicine. Jørgensen JT ed. *Expert Rev Mol Diagn*. 2020; 20(6): 557-559
- The Different Roles of *MET* in the Development and Treatment of Cancer. Jørgensen JT and Møllerup J Eds. *Cancers (Basel)*. 2023; 15(20): 5087